The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
ATP in the tumour microenvironment drives expression of nfP2X7, a key mediator of cancer cell survival
Open accessAbstract
The ATP-gated receptor P2X 7 is expressed in multiple malignant tumours including neuroblastoma, melanoma, prostate, lung and breast. P2X 7 has a significant role in mediating diverse cell responses, which upon dysregulation are associated with tumour initiation and development. The rapid, ATP-mediated activation of P2X 7 induces a fast-inward cation current in cells. However, prolonged ATP-mediated activation of P2X 7 leads to formation of a pore that increases membrane permeability and eventually causes cell death. This presents a potential paradox, as the tumour microenvironment contains extracellular ATP at levels sufficient to activate the P2X 7 pore and trigger cell death. However, P2X 7 expression is associated with enhanced cancer cell survival, proliferation and metastatic potential. At least one distinct conformational form of P2X 7 , termed non-pore functional P2X 7 (nfP2X 7 ), has been described, which is not able to form a functional pore. We demonstrate for the first time in this study that exposure to a high ATP concentration, equivalent to those measured in the tumour microenvironment, drives nfP2X 7 expression and also that nfP2X 7 is essential for tumour cell survival. We show that monoclonal antibodies raised against a P2X 7 amino acid sequence (200–216), whose conformation is distinct from that of wild-type (WT) P2X 7 , bind specifically to nfP2X 7 expressed on the surface of tumour cells. We also show that nfP2X 7 is broadly expressed in patient-derived tumour sections from a wide range of cancers. Therefore, antibodies raised against E200 provide tools that can differentiate between forms of the P2X 7 receptor that have a key role in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Molecular Physiology of P2X Receptors
North, R. A. (2002) · Physiological Reviews · doi:10.1152/physrev.00015.2002 · Cited by 2,919
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898 · cited 2×
“[43] showed that ATP released in the TME drives CD8 T-cells priming by dendritic cells in a P2X7-dependent manner.”
BackgroundThe Cytolytic P 2Z Receptor for Extracellular ATP Identified as a P 2X Receptor (P2X 7 )
Surprenant, A., Rassendren, F., Kawashima, E., North, R. A., & Buell, G. (1996) · Science · doi:10.1126/science.272.5262.735 · Cited by 1,739 · cited 1×
“P2X7 is characterised by a biphasic response [4].”
BackgroundThe P2X7 Receptor in Infection and Inflammation
Di Virgilio, F., Dal Ben, D., Sarti, A. C., Giuliani, A. L., & Falzoni, S. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.020 · Cited by 1,267
Self-citationThe ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase
Pellegatti, P., Raffaghello, L., Bianchi, G., Piccardi, F., Pistoia, V., & Di Virgilio, F. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002599 · Cited by 668
Sluyter, R. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2017_59 · Cited by 235 · cited 1×
“A number of studies have demonstrated that nfP2X7 is expressed at the surface of several cancer types but is absent at the surface of normal tissue [23, 26, 27, 41, 45].”
Background
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
From purines to purinergic signalling: molecular functions and human diseases
Huang, Z., Xie, N., Illes, P., Di Virgilio, F., Ulrich, H., Semyanov, A., Verkhratsky, A., Sperlagh, B., Yu, S.-G., Huang, C., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00553-z · Cited by 489
Self-citationZhang, H., Steed, A., Co, M., & Chen, X. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.32 · Cited by 50
Autocrine and Paracrine Purinergic Signaling in the Most Lethal Types of Cancer
Reyna-Jeldes, M., Díaz-Muñoz, M., Madariaga, J. A., Coddou, C., & Vázquez-Cuevas, F. G. (2021) · Purinergic Signalling · doi:10.1007/s11302-021-09785-8 · Cited by 25
Jafari-Matanagh, S., Razavi, S. E., Ehghaghi Bonab, M. B., Omidian, H., & Omidi, Y. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106477 · Cited by 6
Metadata
- Authors
- Gilbert, S., Oliphant, C., Hassan, S., Peille, A., Bronsert, P., Falzoni, S., Di Virgilio, F., McNulty, S., & Lara, R.
- Venue
- Oncogene
- Published
- 2018-08-07
- Volume
- 38
- Issue
- 2
- Pages
- 194-208
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2886489703
- Cited by
- 197
- References
- 8
- FWCI
- 12.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ATP in the tumour microenvironment drives expression of nfP2X7, a key mediator of cancer cell survival. https://app.cochat.ai/papers/10.1038/s41388-018-0426-6
- The paper
- Gilbert, S., Oliphant, C., Hassan, S., Peille, A., Bronsert, P., Falzoni, S., Di Virgilio, F., McNulty, S., & Lara, R. (2019). ATP in the tumour microenvironment drives expression of nfP2X7, a key mediator of cancer cell survival. Oncogene. https://doi.org/10.1038/s41388-018-0426-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.